On Monday, Esperion Therapeutics Inc (NASDAQ: ESPR) was -7.06% drop from the session before settling in for the closing price of $1.70. A 52-week range for ESPR has been $1.58 – $3.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 9.55% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 84.35%. With a float of $195.08 million, this company’s outstanding shares have now reached $195.44 million.
In an organization with 240 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 81.57%, operating margin of 5.57%, and the pretax margin is -29.37%.
Esperion Therapeutics Inc (ESPR) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Esperion Therapeutics Inc stocks. The insider ownership of Esperion Therapeutics Inc is 0.99%, while institutional ownership is 66.15%. The most recent insider transaction that took place on Feb 19 ’25, was worth 446. In this transaction Chief Commercial Officer of this company sold 239 shares at a rate of $1.87, taking the stock ownership to the 159,759 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Financial Officer sold 11 for $1.86, making the entire transaction worth $20. This insider now owns 240,671 shares in total.
Esperion Therapeutics Inc (ESPR) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 84.35% per share during the next fiscal year.
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
You can see what Esperion Therapeutics Inc (ESPR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.05.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.07 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
Let’s dig in a bit further. During the last 5-days, its volume was 3.66 million. That was inferior than the volume of 4.05 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 9.01%. Additionally, its Average True Range was 0.12.
During the past 100 days, Esperion Therapeutics Inc’s (ESPR) raw stochastic average was set at 0.42%, which indicates a significant decrease from 2.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.78% in the past 14 days, which was lower than the 83.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.0197, while its 200-day Moving Average is $2.1730. However, in the short run, Esperion Therapeutics Inc’s stock first resistance to watch stands at $1.6967. Second resistance stands at $1.8133. The third major resistance level sits at $1.8767. If the price goes on to break the first support level at $1.5167, it is likely to go to the next support level at $1.4533. Assuming the price breaks the second support level, the third support level stands at $1.3367.
Esperion Therapeutics Inc (NASDAQ: ESPR) Key Stats
There are 197,035K outstanding shares of the company, which has a market capitalization of 311.32 million. As of now, sales total 116,330 K while income totals -209,250 K. Its latest quarter income was 51,630 K while its last quarter net income were -29,520 K.
